On April 22, 2024, CNNC Gaotong, a subsidiary of China National Nuclear Corporation (CNNC) announced:
The first production line of 10000 curie level carrier free lutetium-177 and the production line of 1000 curie level germanium gallium [68Ge-68Ga] generators in China have been fully completed and put into operation, marking that China officially has the production and supply capacity for the two medical nuclides, including 10000 curie level lutetium-177 and gallium-68. This truly realizes the large-scale commercial supply of produced nuclides and effectively alleviates the problem of insufficient supply and dependence on imports for the two nuclides in China.
 |
It is reported that the two products, CNNC Gaotong Lutetium-177 and Gallium-68, meet the requirements of EMA (European Medicines Administration) standards in terms of production line design, production technology, quality indicators, equipment and facilities, and management system. They are at the top tier in the world and have obvious international competitive advantages. Subsequently, CNNC Gaotong will enter the international market and participate in the international medical nuclide industry chain circulation.
In addition, CNNC Gaotong can officially supply two emerging nuclides, Terbium 161 and Scandium 47, at the Curie level. Terbium 161, scandium 47, and lutetium-177 have similar decay, biochemical, and in vivo properties, as well as unique advantages, which will bring new opportunities and possibilities for the development of nuclear medicine.